BESPONSA INJECTION 1 MG SPECIAL INVESTIGATION
Latest Information Update: 07 Oct 2024
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 03 Oct 2024 Status changed from active, no longer recruiting to completed.
- 19 Sep 2024 Planned End Date changed from 16 Aug 2024 to 1 Sep 2024.
- 19 Sep 2024 Planned primary completion date changed from 16 Aug 2024 to 1 Sep 2024.